STK11 mutation status is associated with decreased survival in meningiomas

Background Emerging evidence suggests that STK11 mutations may influence clinical outcome and response to immunotherapy in cancer. Materials and methods Next-generation targeted sequencing of STK11 mutation status in a large cohort of 188 meningiomas. Results STK11 loss-of-function mutations were id...

Full description

Saved in:
Bibliographic Details
Published in:Neurological sciences 2020-09, Vol.41 (9), p.2585-2589
Main Authors: Gill, Corey M., Loewenstern, Joshua, Rutland, John W., Arib, Hanane, Pain, Margaret, Umphlett, Melissa, Kinoshita, Yayoi, McBride, Russell B., Bederson, Joshua, Donovan, Michael, Sebra, Robert, Fowkes, Mary, Shrivastava, Raj K.
Format: Article
Language:English
Subjects:
AMP-Activated Protein Kinase Kinases
Brain cancer
Cohort Studies
Genotyping
Humans
Immunotherapy
Medicine
Medicine & Public Health
Meningeal Neoplasms - genetics
Meningeal Neoplasms - therapy
Meningioma
Meningioma - genetics
Meningioma - therapy
Mutation
Neurology
Neuroradiology
Neurosciences
Neurosurgery
Original Article
Protein Serine-Threonine Kinases - genetics
Psychiatry
Survival
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Emerging evidence suggests that STK11 mutations may influence clinical outcome and response to immunotherapy in cancer. Materials and methods Next-generation targeted sequencing of STK11 mutation status in a large cohort of 188 meningiomas. Results STK11 loss-of-function mutations were identified in 3.7% of meningiomas. STK11 mutations were found in both low- and high-grade lesions and samples from primary and recurrent disease. There was a 2.8-fold increased risk of death for patients whose meningioma harbored an STK11 mutation, after controlling for lesion grade and occurrence status. The median overall survival for patients with STK11 -mutated meningiomas was 4.4 years compared with 16.8 years. Conclusion These data identify recurrent STK11 mutations in a subset of meningiomas. Genotyping of STK11 is encouraged for meningioma patients undergoing immunotherapy-based therapy.
ISSN:1590-1874
1590-3478
DOI:10.1007/s10072-020-04372-y